---
title: "SSY GROUP's two products received production registration approval from the National Medical Products Administration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280896891.md"
description: "SSY GROUP announced that Sodium Lactate Ringer's Injection (3000ml) and Bumetanide Injection (2ml:1mg) have obtained the drug production registration approval from the National Medical Products Administration of China, both classified as Class 3 chemical drugs, equivalent to passing the consistency evaluation"
datetime: "2026-03-29T05:19:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280896891.md)
  - [en](https://longbridge.com/en/news/280896891.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280896891.md)
---

# SSY GROUP's two products received production registration approval from the National Medical Products Administration

SSY GROUP (02005.HK) announced that Sodium Lactate Ringer's Injection (3000ml) and Buprenorphine Injection (2ml:1mg) have obtained the drug production registration approval from the National Medical Products Administration of China, both classified as Category 3 chemical drugs, equivalent to passing the consistency evaluation

### Related Stocks

- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

- [SSY Group wins China NMPA approval for emedastine difumarate eye drops 0.05%](https://longbridge.com/en/news/287187916.md)
- [Shanghai Henlius wins Australia clearance to start Phase 1 HLX3902 cancer trial](https://longbridge.com/en/news/287190785.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)